K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$5.15
Prev. Close
$5.91
Prev. Day's Range
$5.15 - $6.05
52W Range
$1.18 - $86.28
Trading Volume
256.29K
MC
$44.693M
P/E Ratio
--
EPS
$-2.25
Company Overview
NASDAQ
Brand Engagement Network, Inc. offers conversational AI technology and human-like AI avatars that offer human-like responses with expressions, gestures, and emotions combined with the ability to remember customer details and problem-solving in real-time on mobile devices, computers, and stand-alone kiosks. The company is headquartered in Jackson, Wyoming.
SectorTECHNOLOGY
IndustrySOFTWARE - INFRASTRUCTURE
Headquarters300 DELAWARE AVE, WILMINGTON, DE, UNITED STATES, 19801
BNAI operates as a company in the biotechnology or health-focused sector, specializing in research, development, and commercialization of products or services within this field. The company’s core business likely revolves around cutting-edge solutions addressing specific medical or scientific needs, which positions it uniquely in its industry.
BNAI is part of the broader biotech or pharmaceutical sector, focusing on developing innovative medical or scientific solutions. This places it in an industry that thrives on research advancements, regulatory milestones, and healthcare demands.
BNAI’s revenue is likely driven by the successful development and commercialization of its products or services. Key drivers may include innovation in therapeutic solutions, partnerships or collaborations with other industry players, and approval of its products by regulatory authorities.
Potential risks for BNAI include regulatory hurdles, competition in its sector, changes in healthcare policies, and the high costs associated with research and development. Additionally, the company’s reliance on scientific innovation and product approvals introduces uncertainty regarding revenue flow.
BNAI operates in a competitive industry where it likely faces competition from other biotech or pharmaceutical companies focused on similar therapeutic areas. Key competitors may include both well-established firms and emerging players in the biotechnology space.
As of now, BNAI does not appear to focus on paying dividends, which is common for companies in the biotech industry. Such firms often reinvest profits into research and development to drive future growth and innovation.
Key growth opportunities for BNAI include advancing its clinical pipeline, forming partnerships with larger pharmaceutical companies, expanding its portfolio of approved products, and capitalizing on unmet medical or scientific needs in its field.
BNAI’s valuation is influenced by factors such as its pipeline progress, revenue potential, and market sentiment about its innovations. Comparisons to peers in the biotech sector may depend on metrics like pipeline advancement, market size, and R&D expenditure.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
